Renal cell carcinoma (RCC) has been recognized as a cancer responsive to the activation of the immune system. In the 1980s, interferon-alpha and interleukin-2 were shown to prolong survival, but they were not widely used due to toxicities. Then, vascular endothelial growth factor receptor and mammalian target of rapamycin inhibitors demonstrated clinical benefits and became the principal treatment in the first- and second-line setting of metastatic RCC (mRCC). In recent years, the efficacy of immune checkpoint inhibitors (ICIs) is confirmed, either alone or in combination with ICI or antiangiogenic agents. ICI-based immunotherapies have now changed the landscape of treatment of mRCC. In this article, we will review the progress of immunotherapy in clear-cell mRCC.
Background: Nectin-4 is a key therapeutic target of antibody–drug conjugates (ADCs) in advanced urothelial carcinoma (UC), but its expression patterns and underlying biology across anatomical sites remain poorly understood. Objectives: This study aimed to elucidate Nectin-4-related features in bladder (urinary bladder carcinoma, UBC) and upper urinary tract (upper tract urothelial carcinoma, UTUC) through a multi-layered approach, including primary tumor characterization, paired primary–metastatic analyses, and immune transcriptomic profiling. Design: A retrospective cohort study. Methods: We retrospectively analyzed primary tumors from 139 patients with advanced UC, including 56 with paired metastatic specimens and 75 with sufficient primary tumor tissue for immune profiling. Membranous Nectin-4 expression was assessed by immunohistochemistry and categorized as Nectin-4 High (H-score 100–300) or Nectin-4 Low (0–99). Immune profiling was performed using the nCounter ® PanCancer Immune Profiling Panel (NanoString Technologies). External transcriptomic datasets (UBC: TCGA-BLCA; UTUC: GSE244957) were used to assess the consistency of immune profiling results. Results: Primary UBC tumors exhibited significantly higher Nectin-4 expression than UTUC tumors (median H-score 150.0 vs 95.0, p = 0.005; Nectin-4 High 70.6% vs 50.0%, p = 0.018). Among paired specimens, 33.9% (19/56) showed primary–metastatic changes in Nectin-4 status, which occurred more frequently in UBC than in UTUC (52.2% vs 21.2%, p = 0.017). Immune profiling revealed a relatively immune-depleted pattern in Nectin-4 High versus Nectin-4 Low tumors in UBC, whereas this pattern was less evident in UTUC. These findings were consistent with those from external transcriptomic datasets. Conclusion: UBC and UTUC demonstrate distinct Nectin-4 expression patterns and associated immune contexture, highlighting the biological heterogeneity of Nectin-4 in advanced UC. Further prospective studies are warranted to validate these findings and clarify their clinical implications.
1 October 2024 in Journal of Cancer Research and Practice
Soft-tissue metastasis from urothelial carcinoma is a rare but advanced disease entity. We report a patient with muscle-invasive bladder cancer who experienced rapid disease recurrence following radical surgery and adjuvant platinum-based chemotherapy. Despite further treatment with taxane-based chemotherapy and immune checkpoint inhibitors, the patient developed diffuse soft-tissue metastases, including in the skin, muscles of the extraocular area, extremities, and trunk. Salvage treatment with enfortumab vedotin (EV) was administered along with local radiation therapy to the orbital metastasis for better symptom control. Unexpectedly, the soft-tissue metastases showed a dramatic response after the first cycle of EV. However, after two cycles of EV treatment, the skin and extremity muscular metastases progressed, while the extraocular metastasis remained controlled. Four months after EV treatment, the patient died due to systemic progression and infection.
16 October 2024 in Journal of the Formosan Medical Association